![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
the price i bought seems high Direxion Daily Financial Bull 3X Shares ETF
FAS
Spdr S&P Bank Etf
KBE
Ultra Financials Proshares
UYG
4
SPDR S&P Metals & Mining ETF
XME
5
SPDR S&P Retail ETF
XRT
US Stock MarketDetailed Quotes
Pelthos Therapeutics (PTHS)
- 21.830
- -0.420-1.89%
Close Dec 16 15:59 ET
67.38MMarket Cap-1.48P/E (TTM)
22.405High21.370Low7.91KVolume22.200Open22.250Prev Close173.63KTurnover0.65%Turnover RatioLossP/E (Static)3.09MShares54.29052wk High1.16P/B26.66MFloat Cap5.89552wk Low--Dividend TTM1.22MShs Float60.000Historical High--Div Yield TTM4.65%Range %4.500Historical Low21.959Avg Price1Lot Size
PTHS Stock Chart
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
PTHS Orderflow
Unit: --
PTHS Orderflow Trend
IntradayDayWeekMonth
No Data
Pelthos Therapeutics (PTHS) News
Analysts Offer Insights on Healthcare Companies: Novan (NOVN), Pelthos Therapeutics (PTHS) and Scholar Rock Holding (SRRK)
Lake Street Maintains Pelthos Therapeutics(PTHS.US) With Buy Rating, Maintains Target Price $50
Analysts Are Bullish on These Healthcare Stocks: Pelthos Therapeutics (PTHS), Praxis Precision Medicines (PRAX)
Pelthos Signs Benefit Manager Agreement Expanding Patient Access to ZELSUVMI
Pelthos Signs First Big Deal to Expand Access to Its At-Home Treatment for Molluscum
Express News | Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to Zelsuvmi™ (Berdazimer) Topical Gel, 10.3%
Pelthos Therapeutics (PTHS) Stock Forum
$Biofrontera (BFRI.US)$
$Pelthos Therapeutics (PTHS.US)$
Pelthos Therapeutics Inc. (NYSE:PTHS) on Friday acquired the U.S. commercialization rights to Xepi (ozenoxacin) Cream, 1%, from Biofrontera Inc. (NASDAQ:BFRI) and Ferrer Internacional S.A.
PTHS shares are showing limited movement. Get the market research here
Xepi is a non-fluorinated quinolone antimicrobial indicated for the topical trea...
$Pelthos Therapeutics (PTHS.US)$
Pelthos Therapeutics Inc. (NYSE:PTHS) on Friday acquired the U.S. commercialization rights to Xepi (ozenoxacin) Cream, 1%, from Biofrontera Inc. (NASDAQ:BFRI) and Ferrer Internacional S.A.
PTHS shares are showing limited movement. Get the market research here
Xepi is a non-fluorinated quinolone antimicrobial indicated for the topical trea...
$Pelthos Therapeutics (PTHS.US)$ BTCbeast Appreciate the advice given. I am just pointing out what you said earlier — you were looking for 50–60. If that changed, cool, but no need to get hostile. Think my poor english make you unhappy. Should use "looking for" instead of "target". By the way, I’m just trying to learn. Everyone starts somewhere, and asking questions doesn’t make someone a clown — it shows they care.
$Pelthos Therapeutics (PTHS.US)$ Big News
Pelthos Therapeutics Launches ZELSUVMI™ (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum
Pelthos Therapeutics Launches ZELSUVMI™ (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum
1
$Pelthos Therapeutics (PTHS.US)$ needs to hold 16.09 as mentioned in prior post
1
$Pelthos Therapeutics (PTHS.US)$ When asks are posted below current price/ bids higher than current price is a dead giveaway stock is being shorted. I got some shares at 16.91 so thanks for the discount 😁
1
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)